Orexigen Insists It Can Grow Contrave After Takeda Exit
This article was originally published in The Pink Sheet Daily
Executive Summary
Beware the Ides of March, especially if you're an investor in the obesity drug market. Orexigen added further evidence that the market is crumbling as it hitched its wagon to a partner that is even worse off.